+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cold Agglutinin Disease (CAD) - Epidemiology Forecast - 2028

  • ID: 4845147
  • Report
  • September 2019
  • Region: Global
  • 91 pages
  • DelveInsight
1 of 2
‘Cold Agglutinin Disease (CAD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China, and Taiwan.

Geography Covered
  • Asia (Taiwan and China)
  • Middle East (Saudi Arabia and UAE)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina, and Colombia)
Study Period:2017-2028

CAD - Disease Understanding and Treatment Algorithm

CAD is a type of autoimmune hemolytic anemia (AIHA) which consist of warm, cold, or mixed-reactive antibody types that are directed against antigens on the red blood cell (RBC) surface. The autoantibodies may be idiopathic or related to an underlying condition, such as infection, malignancy, or immune disease.

Thus, based on the autoantibodies, CAD is classified as primary (unknown cause) or secondary (caused by an underlying condition). Primary Cold Agglutinin Disease is used to describe patients without other systemic autoimmune disease or infective etiology and who have no clinical or radiological evidence of underlying lymphoma. Secondary Cold Agglutinin Disease, is mediated by hemolytic anemia occasionally complicating other specific diseases, such as B cell neoplasias (CLL, Waldenstrom macroglobulinemia, myeloma, other lymphomas), solid tumors (squamous carcinoma of the lung, metastatic adenocarcinoma of the colon, basal cell carcinoma, metastatic adrenal carcinoma, mixed parotid tumor), infections (most frequently Mycoplasma pneumonia, Epstein-Barr virus) or autoimmune diseases (scleroderma, primary Sjogren's syndrome, adult Still's disease, SLE, rheumatoid arthritis). The responsible antibody is monoclonal IgM in B-cell neoplasias and solid tumors and polyclonal IgM in infections, connective tissue diseases, and non-Hodgkin lymphomas.

CAD Epidemiology

The CAD epidemiology division provides insights about historical and current patient pool and forecasted trends of 10EM countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent cases, Gender-Specific Prevalence, Age-Specific Prevalence and Type-Specific Prevalent cases of CAD ) scenario of CAD in 10 Emerging Markets (EM) i.e. Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China and Taiwan for the study period 2017-2028.

According to this report, the total prevalent cases of CAD in the 10EM was found to be 29,077 in 2017. The total prevalent cases for Cold Agglutinin Disease (CAD) were highest in China, while Russia and U.A.E. accounted for the least number of prevalent cases. In the case of Type-Specific cases, Primary CAD and Secondary CAD are reported in nearly equal proportions in all the 10EM countries. However, Primary CAD is commonly observed and easily treated in comparison to secondary CAD. The prevalence of CAD in the 10EM is expected to increase during the study period of 2017-2028.

CAD Report Insights
  • The report covers a descriptive overview of the CAD, explaining its signs and symptoms, clonality and histopathology, pathogenesis and diagnosis.
  • Comprehensive insight has been provided into the epidemiology CAD in the 10EM countries covering Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China, and Taiwan.
  • Assesses growth opportunities in 10EM countries with respect to the patient population.
CAD Report Key Strengths
  • 10-Year Forecast
  • 10 EM Coverage
  • Epidemiology Segmentation by Type of CAD
  • Total Patient Pool of CAD
  • Gender-Specific Diagnosed Patient Pool of CAD
  • Age-Specific Diagnosed Patient Pool of CAD
  • Type-Specific Diagnosed Patient Pool of CAD
CAD Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
Key Benefits
  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by type
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Cold Agglutinin Disease: Patient Overview at a Glance
2.1. Patient Share (%) Distribution of Cold Agglutinin Disease in 2017
2.2. Patient Share (%) Distribution of Cold Agglutinin Disease in 2028

3. Cold Agglutinin Disease: Disease Background and Overview
3.1. Introduction
3.2. Signs and Symptoms
3.3. Clonality and Histopathology
3.4. Pathogenesis
3.5. Diagnosis

4. Epidemiology and Patient Population - By Region
4.1. Key Findings

5. Ten Emerging Markets (10EM) - Epidemiology
5.1. Total Prevalence of Cold agglutinin disease in 10 Emerging Markets

6. Region Wise-Epidemiology of Cold Agglutinin Disease (CAD)
6.1. Assumptions and Rationale
6.2. Asia [Taiwan and China]
6.3. Taiwan
6.3.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Taiwan
6.3.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
6.3.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
6.3.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Taiwan
6.4. China
6.4.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in China
6.4.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in China
6.4.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in China
6.4.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in China
6.4.5. Middle East [Saudi Arabia and UAE]
6.5. Saudi Arabia
6.5.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
6.5.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
6.5.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
6.5.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Saudi Arabia
6.6. UAE
6.6.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in the UAE
6.6.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
6.6.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
6.6.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in the UAE
6.7. Eastern Europe [Russia and Turkey]
6.8. Russia
6.8.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Russia
6.8.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
6.8.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
6.8.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Russia
6.9. Turkey
6.9.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Turkey
6.9.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
6.9.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
6.9.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Turkey
6.10. LATAM [Mexico, Brazil, Argentina and Colombia]
6.11. Mexico
6.11.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Mexico
6.11.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
6.11.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
6.11.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Mexico
6.12. Brazil
6.12.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Brazil
6.12.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
6.12.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
6.12.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Brazil
6.13. Argentina
6.13.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Argentina
6.13.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
6.13.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
6.13.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Argentina
6.14. Colombia
6.14.1. Prevalent Cases of Cold Agglutinin Disease (CAD) in Colombia
6.14.2. Gender-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia
6.14.3. Type-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia
6.14.4. Age-Specific Cases of Cold Agglutinin Disease (CAD) in Colombia

7. Unmet Needs

8. Market Drivers

9. Market Barriers

10. KOL Views

11. Appendix
11.1. Report Methodology

12. Capabilities

13. Disclaimer

14. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll